Methotrexate (MTX): Clinical Trials

48 trials of Methotrexate (MTX), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 9 recruiting, 4 not yet recruiting, 4 unknown. 18 Phase 2, 12 Phase 3, 9 Phase 4, 6 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 218Completed 8, Recruiting 6, Not yet recruiting 2, Terminated 2
Phase 312Completed 8, Recruiting 2, Not yet recruiting 1, Unknown 1
Phase 49Completed 7, Recruiting 1, Unknown 1
Phase 16Completed 4, Unknown 2
Not applicable1Completed 1

Follow Methotrexate (MTX): new trials by email Literature Review of Methotrexate (MTX) trials Research Report on Methotrexate (MTX)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
MK-8690, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis
Phase 2Not yet recruitingMerck Sharp & Dohme LLC602026-11-232026-11-16
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
Natrunix 400 mg, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis
Phase 2Not yet recruitingXBiotech, Inc.1082026-07-152025-12-09
Methotrexate for Severe Vulvar Lichen Sclerosus
Methotrexate (MTX) - Vulvar Lichen Sclerosus
Phase 2RecruitingClinica Dermatologica Arbache ltda122026-01-212026-01-22
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
PRX-115, Methotrexate (MTX), PRX-115 placebo - Gout
Phase 2RecruitingProtalix1502025-12-222026-09-29
Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis
Phase 2RecruitingUniversity of Pennsylvania202025-11-112026-09-02
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Hydroxychloroquine (HCQ), Methotrexate (MTX) - Frontal Fibrosing Alopecia, Cicatricial Alopecia
Not yet recruitingErasmus Medical Center502025-11-012025-09-29
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Lenalidomide, Methotrexate (MTX) - Cutaneous Lupus Erythematosus (CLE)
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris1222025-10-012025-05-11
Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA
Methotrexate (MTX), Placebo - Osteo Arthritis of the Knee, Synovitis of Knee
Phase 2RecruitingBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh702025-07-302025-09-12
Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study)
Methotrexate (MTX) - Rheumatoid Arthritis (RA)
Phase 4RecruitingKeio University1002025-04-102025-04-06
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) - Graft-versus-host Disease (GVHD)
Phase 3RecruitingIncyte Corporation5722025-04-022026-10-22
ZR-MTX for PIOL Phase II Trial
Methotrexate, Rituximab (R), Zanubrutinib - Primary Intraocular Lymphoma
Phase 2RecruitingPeking Union Medical College Hospital472024-10-102026-09-04
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET)
Phase 2RecruitingIcahn School of Medicine at Mount Sinai542024-10-022025-12-17
Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma
Glucarpidase, Methotrexate (MTX) - Primary Central Nervous System Lymphoma
Phase 1UnknownAssistance Publique - Hôpitaux de Paris182022-09-152022-10-25
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
Orelabrutinib, Rituximab, Methotrexate (MTX) - Primary Central Nervous System Lymphoma
Phase 1CompletedHuashan Hospital132021-10-102026-08-19
Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
Pegloticase, Methotrexate (MTX) - Uncontrolled Gout
Phase 4CompletedAmgen112021-03-082024-06-27
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
Pegloticase, Methotrexate (MTX) - Uncontrolled Gout, Chronic Gout
Phase 4CompletedAmgen542021-01-262026-05-19
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients
GB224 10mg, GB224 20mg - Rheumatoid Arthritis
Phase 1UnknownGenor Biopharma Co., Ltd.242019-08-152019-11-27
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
ATG, CTX, Mycophenolate Mofetil - Hematopoietic Stem Cell Transplantation
Phase 4UnknownNanfang Hospital, Southern Medical University2602018-10-292019-10-28
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis - Gout
Phase 4CompletedAmgen142018-09-262024-06-26
Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis
Fecal microbiota transplantation (FMT), Drug: Placebo (saline), Methotrexate (MTX) - Psoriatic Arthritis
Not applicableCompletedOdense University Hospital312017-05-162020-12-07

Showing 20 of 48. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (23)  ·  Gout (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Arthritis, Psoriatic (3)  ·  Graft vs Host Disease (3)  ·  Arthritis (2)  ·  Leukemia (2)  ·  Lymphoma (2)  ·  Alopecia (1)  ·  Autoimmune Diseases (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Burkitt Lymphoma (1)  ·  Hair Diseases (1)  ·  Hodgkin Disease (1)  ·  Hyperuricemia (1)

Sponsors

Amgen (3)  ·  Pfizer (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Centocor, Inc. (2)  ·  Chelsea Therapeutics (2)  ·  M.D. Anderson Cancer Center (2)  ·  Merck Sharp & Dohme LLC (2)  ·  AbbVie (1)  ·  Antares Pharma Inc. (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Astellas Pharma Inc (1)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Bristol-Myers Squibb (1)  ·  Clinica Dermatologica Arbache ltda (1)  ·  Eastern Cooperative Oncology Group (1)

Countries

United States (23)  ·  China (5)  ·  Spain (5)  ·  Australia (4)  ·  Canada (4)  ·  Colombia (4)  ·  Czechia (4)  ·  Germany (4)  ·  Italy (4)  ·  Japan (4)  ·  Mexico (4)  ·  Poland (4)  ·  Belgium (3)  ·  United Kingdom (3)  ·  Argentina (2)

Top investigators

Alan J Kivitz, MD;CPI (1)  ·  Alice B. Gottlieb, M.D., PhD. (1)  ·  Arthur A Kavanaugh, MD (1)  ·  Claudio Anasetti, MD (1)  ·  Edward Keystone, MD (1)  ·  Francine M. Foss, MD (1)  ·  James R O'Dell, MD (1)

Results publications

PMID 18047523, PMID 21724705, PMID 21994233, PMID 22121129, PMID 22689677, PMID 23097311, PMID 24001888, PMID 24752047, PMID 24786931, PMID 25623393, PMID 25946554, PMID 26139005, PMID 27863807, PMID 28035867, PMID 28153828, PMID 28494788, PMID 29427176, PMID 29575803, PMID 29703851, PMID 31429794, PMID 32100960, PMID 32934137, PMID 33926922, PMID 34006020, PMID 35183373, PMID 35293984, PMID 35313978, PMID 36008814, PMID 36058784, PMID 36575505, PMID 38288922, PMID 38296309, PMID 39222436, PMID 40814761

NIH funding

2016 (2), 2008 (1), 2009 (1), 2015 (1), U10CA021115 (1)